EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy's Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") RDY between June 17, 2015 and August 10, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:

http://www.zlk.com/plsra-c/dr-reddys-laboratories-ltd?wire=2

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Dr. Reddy's lacked an effective corporate quality system; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy's announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy's manufacturing plants in India. Then on August 10, 2017, Dr. Reddy's disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy's German subsidiary Betapharm Arzneimittel, located in India.

If you suffered a loss in Dr. Reddy's you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170914006103/en/